

Introducing MTIP EverHealth Fund

Healthcare Private Equity with Focus on Europe

This is a marketing communication.

MTIP EverHealth Fund – Terms

Fund Name	MTIP EverHealth Fund SA, SICAV-OPC Partie II, ELTIF
Target Fund Size	Growth trajectory to €300m+
Investment Strategy & Focus	Healthcare private equity with emphasis on Europe[1]
Fund Type / Term	Semi-liquid, open-ended structure (evergreen)
Fund Domicile	Luxembourg under AIFMD
Share Classes	Standard share class per currency for investors with bankable ISIN
Currencies	▪ EUR ▪ CHF
Min. Ticket Size	Min. investment: €100'000[2]

Target Net Return	15-20% p.a.*
Subscriptions	Quarterly[2]
Fee Structure	▪ Management fee: 1.35% p.a. on NAV ▪ Performance fee: 15% on realized deals with an 8% preferred return p.a., combined with a high watermark[3]
Liquidity	Quarterly, up to 1/3 of liquid NAV[4]
Reporting	▪ Quarterly reporting ▪ Annual financial statements
Deposit of Funds	Share price fully paid-in
Holding Period	3 years minimum, 8 years recommended

1. The Fund mainly targets growth and buyout opportunities, complemented by selective venture investments, and may invest through majority, minority or non-controlling positions.
2. Or at discretion of the board of the Fund.
3. Payment of performance fee is further conditioned on a rolling 24-months high-watermark.
4. Following the initial three-year minimum investment period, investors may submit redemption requests quarterly with at least three months' prior notice. The aggregate amount of redemptions that may be honored on a quarterly redemption date is generally limited to 33.3% of the Fund's available liquid assets. A 1% redemption fee applies and is credited to the Fund for the benefit of remaining investors. Redemption requests may be deferred, suspended, restricted or refused where necessary to protect remaining investors, avoid liquidity mismatches and ensure the orderly realization of assets. Redemptions are subject to the Fund's liquidity and the terms of the prospectus and articles.

*The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and/or current market conditions and are not an exact indicator. What you will get will vary depending on how the market performs and how long you keep the investment. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. Investing involves risks and may lead to a financial loss. The value of an investment and the income from it may fall as well as rise, investors may not get back the full amount invested, and no guarantee of capital is in place.

The MTIP EverHealth Fund is actively managed. Investors acquire units or shares in the Fund and do not invest directly in the Fund's underlying assets, including its portfolio companies.

Disclaimer 1 / 2

This is a marketing communication. Please refer to the prospectus of the AIF and to the PRIIPs KID before making any final investment decisions.

Important: An investment in the MTIP EverHealth Fund involves the acquisition of **units or shares in the Fund** and does **not constitute a direct investment in the Fund's underlying assets,** including shares in portfolio companies held by the Fund. The Fund is actively managed, and investment selection and portfolio construction are undertaken on a discretionary basis in accordance with the Fund's investment policy.

This marketing communication is intended exclusively for professional investors and is not intended for retail investors. For professional investors only, strictly private and confidential solely for the intended recipient.

Investments in interests in MTIP EverHealth Fund SA, SICAV-OPC Partie II, ELTIF are highly illiquid and designed for professional investors pursuing a long-term investment strategy only. Investors are advised that only a small portion of their overall investment portfolio should be invested in the Fund.

This document is an incomplete draft. It does not contain sufficient information to allow potential investors to take an investment decision. It does not constitute an offer or an invitation to subscribe for interests, units or shares of an alternative investment fund. The information presented herein should not be relied upon, since it is not final, incomplete and may be subject to change.

Target return assumptions may be based on the investment team's experience with predecessor funds, market participants and other stakeholders of the industry. Actual returns from an investment in the portfolio over any given time horizon may vary significantly from the target return assumptions.

Expected future performance: The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies and/or current market conditions and are not an exact indicator. What you will get will vary depending on how the market performs and how long you keep the investment. Future performance is subject to taxation, which depends on each investor's personal circumstances and may change in the future. An investment may lead to a financial loss, and no guarantee of capital is in place.

To the extent we express any prognoses or expectations in this document or make any forward-looking statements, these statements may involve known and unknown risks and uncertainties. Actual results and developments may therefore differ materially from the expectations and assumptions made. On our part, there is no obligation to update target return assumptions and forward-looking statements presented herein.

Investing involves risk. The value of an investment and the income from it may fall as well as rise and investors might not get back the full amount invested. Past performance is not a reliable indicator of future results. Be aware of currency risk. Investors may receive payments in a currency different from their own, and the final return may depend on the exchange rate between the relevant currencies. This risk may not be reflected in the summary risk indicator shown in the PRIIPs KID. The Fund does not provide protection against future market performance, and investors may lose some or all of their investment. If the Fund is not able to pay what is owed, investors could lose some or all of their investment. Poor market conditions may materially affect the Fund's ability to make payments to investors. The views and opinions expressed herein, which are subject to change without notice, are those of the issuer companies at the time of publication. The data used is derived from various sources and assumed to be correct and reliable at the time of publication.

The Fund has been established for an unlimited duration. It may be dissolved or wound up in accordance with the conditions and procedures described in the prospectus. As the Fund has no fixed end date, there is no ordinary option to extend its life.

The share classes currently offered are accumulation share classes and do not pay dividends. Accordingly, no regular distributions of income or investment proceeds are planned during the life of the Fund. Income and capital gains are retained and capitalized within the relevant share class.

Financial derivative instruments may be used only to hedge risks inherent in the Fund's other investments, including foreign-currency and interest-rate risks. Hedging may reduce certain exposures but may also introduce costs, counterparty risk and imperfect-hedging risk, and may therefore affect the Fund's overall risk profile.

The Fund invests principally in private and other unlisted assets that may be difficult to sell and for which no readily available secondary market or observable market price may exist. These assets may be valued using fair-value models, estimates and professional judgement. As a result, the reported NAV may differ from the price ultimately realized on disposal. Asset-level illiquidity may also compound the Fund's redemption restrictions and delay its ability to meet redemption requests.

Disclaimer 2 / 2

Investors will be informed at least annually, through the Fund's reporting, of the jurisdictions in which the Fund has invested.

SFDR classification: The MTIP EverHealth Fund is classified as an Article 6 financial product under SFDR. The Fund does not promote environmental or social characteristics and does not have sustainable investment as its objective.

For investors in the European Economic Area (EEA)

For a free copy of the articles, the prospectus, the subscription agreement, the PRIIPs KID and the latest semi-annual or annual report, please contact Fundcraft Management S.à r.l., either electronically or by mail, at the given address of its registered office indicated below, or access these documents free of charge at [INSERT DIRECT DOCUMENT URL]. The prospectus is available in English and German. The PRIIPs KID is available in English and German. Please read these documents, which are solely binding, carefully before investing.

For complete information on the risks associated with the Fund, please refer in particular to the "Risk Factors" section of the prospectus and the relevant risk disclosures in the PRIIPs KID. These documents are available free of charge from Fundcraft Management S.à r.l. and at [INSERT DIRECT DOCUMENT URL].

A summary of investor rights, including information on access to collective redress mechanisms at Union and national level in the event of litigation, is available free of charge in English and German.

This is a marketing communication issued by Fundcraft Management S.à r.l., with its registered office at 12, rue des Mérovingiens, L-8070 Bertrange, Grand Duchy of Luxembourg, authorised by the Luxembourg financial market supervisory authority (Commission de surveillance du secteur financier, www.cssf.lu). Fundcraft Management S.à r.l. may terminate arrangements made for marketing, including by way of de-notification.

The duplication, publication, or transmission of any content of the articles, the prospectus, the subscription agreement and the latest semi-annual or annual report relating to MTIP EverHealth Fund SA, SICAV-OPC Partie II, ELTIF, irrespective of the form, is not permitted, except for the case of explicit permission by Fundcraft Management S.à r.l..

For Swiss Investors

This is an advertising document.

The Fund may only be offered in Switzerland to qualified investors within the meaning of Art. 10 para. 3 and 3ter CISA. In Switzerland, the representative and the paying agent is REYL & Cie Ltd, Rue du Rhône 4, CH-1204 Geneva.

The relevant documents of the Fund, including the prospectus, the PRIIPs KID and the annual report, may be obtained free of charge from the representative and at [INSERT DIRECT DOCUMENT URL]. The prospectus is available in English and German. The PRIIPs KID is available in English and German and the PRIIPs KID is available in English and German.

For complete information on the risks associated with the Fund, please refer in particular to the "Risk Factors" section of the prospectus and the relevant risk disclosures in the PRIIPs KID, available free of charge from REYL & Cie Ltd.

In respect of the units offered in Switzerland, the place of performance is the registered office of the representative. The place of jurisdiction is at the registered office of the representative or at the registered office or place of residence of the investor.

Let's Stay in Touch



Rittergasse 35
CH-4051 Basel
Switzerland

P +41 61 551 02 50
E info@mtip.ch

www.mtip.ch

Sign up for our newsletter **here**.

Follow us on Linkedin **here**.
@mtip-healthcare-technology-investors